6533b825fe1ef96bd1281ecf
RESEARCH PRODUCT
Efavirenz induces alterations in lipid metabolism through AMPK activation
Milagros RochaJuan V. EspluguesVictor M. VictorJosé Manuel MoralesDaniel MonleonNadezda ApostolovaAna Blas-garciaDaniel Ballesterossubject
medicine.medical_specialtyEfavirenzbusiness.industryPublic Health Environmental and Occupational HealthAMPKLipid metabolismmedicine.diseasechemistry.chemical_compoundInfectious DiseasesEndocrinologychemistryInternal medicinemedicineLipodystrophybusinessProtein kinase ALipoatrophyIntracellularCompound cdescription
Summary of results EFV produced an immediate reduction of mitochondrialfunction, evident by the significant and dose-dependentinhibition of mitochondrial O2 consumption and thedecrease of intracellular ATP and Δψm. This metabolicstress promoted the activation of AMPK, triggering severalof its signalling pathways, as EFV induced an increment inCD36 mRNA expression and in intracellular lipid content,which could have been a result of the formation of lipiddroplets. This intracellular lipid increase was not presentin cells treated with Compound C, which points to a keyrole for AMPK in these mechanisms. Conclusion Given that EFV treatment is usually prolonged, thesemechanisms may effect the general regulation of lipidmetabolism and could cause the alterations that are char-acteristic of lipoatrophy. References 1. Blanco F: Involvement of Efavirenz in Lipodystrophy. AIDSReviews 2004, 6: 117-9.2. Viollet B, et al. : Activation of AMP-activated protein kinase inthe liver: a new strategy for the management of metabolichepatic disorders.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 2008-01-01 | Journal of the International AIDS Society |